76
|
Schott R, Franke L, Burghardt R, Doepmann J, Roessner V, Lehmkuhl U, Ehrlich S. Relationships between platelet MAO-B activity and personality styles in acute and weight-recovered young patients with anorexia nervosa. PHARMACOPSYCHIATRY 2012; 46:47-53. [PMID: 22915483 DOI: 10.1055/s-0032-1321869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Previous studies have shown relationships between personality styles and markers of serotonergic functioning, but data on patients with anorexia nervosa (AN) are scarce. METHODS The personality styles and disorder inventory was administered to 47 acute patients with anorexia nervosa (acAN), 27 weight-recovered patients (recAN) and 72 healthy controls (HC) aged between 14 and 21 years. Platelet monoamine oxidase (MAO-B) activity was assayed with [14C]-β-phenylethylamine as substrate. RESULTS AcAN had significant elevated scores on 9 of the 14 personality style subscales when compared to HC, whereas recAN were largely normal. Platelet MAO-B activity and "ambitious/narcissistic" scores correlated negatively in acAN. In recAN we found positive correlations between MAO-B and personality subscores. CONCLUSIONS The inverse relationship between a cluster B personality style and MAO-B activity in acAN is in accordance with studies in other patient populations. In contrast, positive associations between problematic personality styles and MAO-B activity in recAN combined with the overall decreased MAO-B activity in this group adds to the existing evidence suggesting a general dysfunction of the serotonergic system as a trait marker for AN.
Collapse
|
77
|
Merklen-Djafri C, Imbert E, Courouge-Dorcier D, Schott R, Méraud JP, Muller C, Tebacher M, Springinsfeld G, Cribier B, Lipsker D. Pemetrexed-induced Skin Sclerosis. Clin Oncol (R Coll Radiol) 2012; 24:452-3. [DOI: 10.1016/j.clon.2012.01.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2011] [Accepted: 01/24/2012] [Indexed: 11/16/2022]
|
78
|
Chouaid C, Schott R, Falchero L, Bonnetain F, Neaume J, Bennouna J, Tagieva N. Bevacizumab in combination with first-line metastatic chemotherapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the cohort study EOLE. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e18005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18005 Background: EOLE, a large cohort of 423 patients included in 1 year (July 2010 – July 2010) with locally advanced, metastatic or recurrent non-squamous NSCLC, aimed to describe the targeted population receiving first-line bevacizumab (Bev) in addition to chemotherapy with regards to progression-free survival, overall survival, safety and quality of life in real clinical practice. Methods: Patients who received physician’s choice of 1st-line Bev-containing treatment were included in this cohort study. Results: This analysis describes the inclusion data of 417 patients consisting of adenocarcinoma (92%), large cell carcinoma (4%), undifferentiated carcinoma in predominantly non-squamous (3%), bronchoalveolar carcinoma (1%). Patient characteristics were as follow: the median age being 60 (years) [32; 84], more males than females (68%), 40% had a baseline ECOG Performance Status (PS) 0, 47% of PS 1 and 12% of PS 2, most patients had Stage IV disease (91%), 13% of patients had never smoked. Tumor location was reported as central for 17% of patents and among them 4% was in contact with the large vessels. For 3% of the lesions a cavitation was notified; and 20% of included patients had brain metastases. The main comorbidities at the inclusion were: cardiovascular (45%), arterial thromboembolic and /or venous (20%) with pulmonary embolism (3%); related to the tumor lesion - bloody sputum (4%) and hemoptysis (1%). 68% of patients have received the dose of Bev 7.5mg/kg q3w; for 49% of patients Bev was combined with cisplatin/pemetrexed, 24% with carboplatin/paclitaxel, 13% with carboplatin/pemetrexed and 7% with cisplatin/gemcitabine. The EGFR mutation analysis was carried out for about 50% of patients. Conclusions: Compared to AVAil and SAil studies, EOLE cohort included more patients classified as having: a baseline PS of 2 (p <0.0001, Fisher test), a never smoked status (p<0.0001, chi2 test) and an adenocarcinoma (92%) (p<0.0001, chi2 test). Around a half of included patients received combination Bev - cisplatin /pemetrexed.
Collapse
|
79
|
Noël G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli P, Maitrot D. Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas. Int J Radiat Oncol Biol Phys 2012; 82:749-55. [DOI: 10.1016/j.ijrobp.2010.11.073] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2010] [Revised: 11/18/2010] [Accepted: 11/30/2010] [Indexed: 11/26/2022]
|
80
|
Barlesi F, Gervais R, Chouaid C, Souquet P, Lavolé A, Monnet I, Étienne-Mastroiani B, Bérard H, Zalcman G, Domas J, Pichon E, Janicot H, Pérol M, Schott R, Vaylet F, Genet D, Moro-Sibilot D, Fournel P, Falchero L, Amador ML, Scherpereel A. AVAPERL : essai randomisé comparant bevacizumab (BEV)+pemetrexed (PEM) versus BEV en traitement (TRT) de maintenance (MTC) après une chimiothérapie (CT) par CDDP/PEM/BEV chez les patients (pts) avec cancer bronchique non à petites cellules non épide. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
81
|
Bennouna J, Falchero L, Schott R, Bonnetain F, Néaume J, Taguieva N, Chouaid C. Bevacizumab (Avastin®) en association à une chimiothérapie à base de platine chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) non épidermoïde avancé non pré-traité : étude EOLE. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
82
|
Chen H, Cebula H, Schott R, Dietemann JL, Froelich S. Glioblastoma multiforme presenting with ischemic stroke: Case report and review of the literature. J Neuroradiol 2011; 38:304-7. [DOI: 10.1016/j.neurad.2011.01.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2010] [Revised: 11/22/2010] [Accepted: 01/18/2011] [Indexed: 11/25/2022]
|
83
|
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Taillia H, Frappaz D, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Guillevin R, Skrzypski J, Dabakuyo TS, Chinot OL. Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
84
|
Noel G, Kehrly P, Schott R, Froelich S, Boyer P, Fischer-Lokou D, Maitrot D. Adding Biodegradable Carmustine Wafers before a Stupp Schedule Does Not Alter Outcome of Patients with High Grade Brain Tumor. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.569] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
85
|
Noël G, Quetin P, Heymann S, Karamanoukian D, Schott R. Les délais au diagnostic et à la mise en traitement n’altèrent pas les résultats des traitements délivrés aux patients atteints de glioblastome. Cancer Radiother 2009; 13:17-23. [DOI: 10.1016/j.canrad.2008.10.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2008] [Revised: 08/21/2008] [Accepted: 10/03/2008] [Indexed: 11/26/2022]
|
86
|
Patterson J, Cameron A, Smith T, Kummer A, Schott R, Greiner L, Connor J, Foxcroft GR. Responses to exogenous gonadotrophin treatment in contemporary weaned sows. SOCIETY OF REPRODUCTION AND FERTILITY SUPPLEMENT 2009; 66:303-304. [PMID: 19848296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
|
87
|
Ehrlich S, Franke L, Schott R, Salbach-Andrae H, Pfeiffer E, Lehmkuhl U, Uebelhack R. Platelet Monoamine Oxidase Activity in Underweight and Weight-Recovered Females with Anorexia Nervosa. PHARMACOPSYCHIATRY 2008; 41:226-31. [DOI: 10.1055/s-2008-1078749] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
88
|
Pfeifer P, Aston L, Banks M, Barker S, Burress J, Carter S, Coleman J, Crockett S, Faulhaber C, Flavin J, Gordon M, Hardcastle L, Kallenborn Z, Kemiki M, Lapilli C, Pobst J, Schott R, Shah P, Spellerberg S, Suppes G, Taylor D, Tekeei A, Wexler C, Wood M, Buckley P, Breier T, Downing J, Eastman S, Freeze P, Graham S, Grinter S, Howard A, Martinez J, Radke D, Vassalli T, Ilavsky J. Complex pore spaces create record-breaking methane storage system for natural-gas vehicles. CHAOS (WOODBURY, N.Y.) 2007; 17:041108. [PMID: 18163763 DOI: 10.1063/1.2786007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
89
|
Métivier AC, Mennecier B, Grunenberger F, Schumacher C, Schott R, Jeung MY, Schlienger JL, Pauli G, Quoix E. [Pituitary metastases from lung cancer. Five cases]. REVUE DE PNEUMOLOGIE CLINIQUE 2006; 62:231-6. [PMID: 17075547 DOI: 10.1016/s0761-8417(06)75446-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Pituitary metastases are rare and generally asymptomatic. We studied 5 patients with pituitary metastases from lung cancer, illustrating the different clinical features. These metastases were in these cases symptomatic with the manifestation being diabetes insipidus or visual field defect. Histological subtypes from our five patients were as well small cell or non small cell lung cancer. After diagnosis of pituitary metastasis, prognosis seems to be linked to the histological subtype and the stage of lung cancer, rather than to the presence of such metastases.
Collapse
|
90
|
Le Chevalier T, Thezenas S, Breton J, Pujol J, Coudert B, Sun X, Laza M, Quoix E, Schott R, Geneve J. Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7097] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7097 Background: Gemcitabine-cisplatin is one of the reference doublets used in NSCLC. Oxaliplatin is a platin analog which offers a promising efficacy/tolerance profile in NSCLC. The combination of gemcitabine and oxaliplatin has been proven feasible and active in solid tumors. Methods: Patients with chemonaive, measurable, PS 0 or 1, stage IIIB/ IV NSCLC were randomized to receive either gemcitabine 1,250 mg/m2 day 1 & 8 plus oxaliplatin 130 mg/m2 day 1 (GEMOX) or gemcitabine 1,250 mg/m2 day 1 & 8 plus cisplatin 80 mg/m2day 1 (GEMCIS). Cycles were given every 3 weeks. The primary endpoint of the study was the response rate according to the RECIST criteria. Secondary endpoints included tolerance, survival and quality of life. Results: Between October 2003 and December 2004, 130 patients (66 in GEMOX and 64 in GEMCIS) were accrued at 12 centres. Baseline patient characteristics were similar in the 2 groups. Mean age was 61. There were 96 males and 34 females; 27% of patients were PS 0 and 73% were PS 1; 15% had stage IIIB and 85% had stage IV. Median number of cycles was 5 in each group. Objective response rates were 36% in GEMOX (CI 95%: 25%-50%) and 39% in GEMCIS (CI 95%: 28%-54%) respectively. Time to progression was 173 days in the GEMOX group and 163 days in the GEMCIS group. Median survival was 10.8 months in the GEMOX group and 10.4 months in the GEMCIS group. Grade III/IV neutropenia was observed in 38% of patients after GEMOX and 41% after GEMCIS; thrombocytopenia was observed in 40% and 33% of cases respectively. Grade 2+ neurotoxicity was more frequent after GEMOX (18% vs 3%). Conclusions: GEMOX has an activity comparable to GEMCIS and may be an alternative for those patients with advanced NSCLC who have a contra-indication to cisplatin. [Table: see text]
Collapse
|
91
|
Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E. Severe Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005; 172:189-94. [PMID: 15831842 DOI: 10.1164/rccm.200401-006oc] [Citation(s) in RCA: 386] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
RATIONALE Severe pulmonary hypertension occurs occasionally in patients with chronic obstructive pulmonary disease (COPD), but no detailed description of these patients is available. OBJECTIVES To identify and characterize patients with COPD and severe pulmonary hypertension. METHODS Retrospective study of 27 patients with COPD with severe pulmonary hypertension (pulmonary artery mean pressure [Ppa], > or = 40 mm Hg) among 998 patients who underwent right heart catheterization between 1990 and 2002 as part of a workup for chronic respiratory failure during a period of disease stability. RESULTS Of the 27 patients, 16 had another disease capable of causing pulmonary hypertension. The remaining 11 (11 of 998, 1.1%) patients had COPD as the only cause of pulmonary hypertension, with a median Ppa of 48 mm Hg (interquartile range, 46-50). They had an unusual pattern of cardiopulmonary abnormalities with mild to moderate airway obstruction, severe hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide (p < 0.01 compared with a control group of patients with COPD). Exertional dyspnea was more severe (p < 0.01) and survival was shorter (p = 0.0026) than in the control subjects. CONCLUSIONS Severe pulmonary hypertension is uncommon in patients with COPD. When it occurs, another cause must be sought. COPD with severe pulmonary hypertension and no other possible cause shares features with pulmonary vascular diseases, such as idiopathic pulmonary hypertension.
Collapse
|
92
|
Leboucher-Dalimier E, Oks E, Dufour E, Sauvan P, Angelo P, Schott R, Poquerusse A. Experimental discovery of charge-exchange-caused dips in spectral lines from laser-produced plasmas. PHYSICAL REVIEW E 2001; 64:065401. [PMID: 11736229 DOI: 10.1103/physreve.64.065401] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2001] [Indexed: 11/07/2022]
Abstract
We report the first experimental observation of charge-exchange-caused dips (also called x dips) in spectral lines of multicharged ions in laser-produced plasmas. Specifically, in the process of a laser irradiation of targets made out of aluminum carbide, we observed two x dips in the Ly(gamma) line of Al XIII perturbed by fully stripped carbon. From the practical point of view, this opens up a way to experimentally produce not-yet-available fundamental data on charge exchange between multicharged ions, virtually inaccessible by other experimental methods. From the theoretical viewpoint, the results are important because the x dips are the only one signature of charge exchange in profiles of spectral lines emitted by plasmas and they are the only one quasimolecular phenomenon that could be observed at relatively "low" densities of laser-produced plasmas.
Collapse
|
93
|
Chaouat A, Weitzenblum E, Kessler R, Schott R, Charpentier C, Levi-Valensi P, Zielinski J, Delaunois L, Cornudella R, Moutinho dos Santos J. Outcome of COPD patients with mild daytime hypoxaemia with or without sleep-related oxygen desaturation. Eur Respir J 2001; 17:848-55. [PMID: 11488315 DOI: 10.1183/09031936.01.17508480] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of the present study was to compare the evolution of pulmonary haemodynamics and of arterial blood gases in chronic obstructive pulmonary disease (COPD) patients with mild-to-moderate hypoxaemia, with or without sleep-related oxygen desaturation. COPD patients with daytime arterial oxygen partial pressure in the range 56-69 mmHg were included prospectively. Sleep-related oxygen desaturation was defined as spending > or = 30% of the nocturnal recording time with arterial oxygen saturation <90%. From the 64 patients included, 35 were desaturators (group 1) and 29 were nondesaturators (group 2). At baseline (t0), patients with sleep-related desaturation had a significantly higher daytime (mean +/- SD) arterial carbon dioxide partial pressure (Pa,CO2) (44.9 +/- 4.9 mmHg versus 41.0 +/- 4.1 mmHg, p=0.001) whereas mean pulmonary artery pressure (mPAP) was similar in the two groups. After 2 yrs (t2) of follow-up, 22 desaturators and 14 nondesaturators could be re-evaluated, including pulmonary haemodynamic measurements. None of the nondesaturator patients became desaturators at t2. The difference between the two groups in terms of daytime Pa,CO2 was still present at t2. The mean changes in mPAP from t0 to t2 were similar between the two groups, as were the rates of death or requirement for long-term oxygen therapy (American Thoracic Society criteria) during follow-up of up to 6 yrs. The presence of sleep-related oxygen desaturation is not a transitional state before the worsening of daytime arterial blood gases, but is a characteristic of some chronic obstructive pulmonary disease patients who have a higher daytime arterial carbon dioxide partial pressure. Such isolated nocturnal hypoxaemia or sleep-related worsening of moderate daytime hypoxaemia does not appear to favour the development of pulmonary hypertension, nor to lead to worsening of daytime blood gases.
Collapse
|
94
|
Chaouat A, Weitzenblum E, Schott R. In Reply: The Mechanism of Hypoxemia in Liver Disease With Pulmonary Hypertension. Chest 2000. [DOI: 10.1016/s0012-3692(15)48673-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
95
|
Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Enrhart M, Schott R, Levi-Valensi P, Zielinski J, Delaunois L, Cornudella R, Moutinho dos Santos J. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14:1002-8. [PMID: 10596681 DOI: 10.1183/09031936.99.14510029] [Citation(s) in RCA: 148] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The beneficial effects of nocturnal oxygen therapy (NOT) in chronic obstructive pulmonary disease (COPD) patients with mild-to-moderate daytime hypoxaemia (arterial oxygen tension (Pa,O2) in the range 7.4-9.2 kPa (56-69 mmHg)) and exhibiting sleep-related oxygen desaturation remains controversial. The effectiveness of NOT in that category of COPD patients was studied. The end points included pulmonary haemodynamic effects after 2 yrs of follow-up, survival and requirement for long-term oxygen therapy (LTOT). Seventy-six patients could be randomized, 41 were allocated to NOT and 35 to no NOT (control). The goal of NOT was to achieve an arterial oxygen saturation of >90% throughout the night. All these patients underwent polysomnography to exclude an associated obstructive sleep apnoea syndrome. The two groups exhibited an identical meansD daytime Pa,O2 of 8.4+/-0.4 kPa (63+/-3 mmHg) at baseline. Twenty-two patients (12 in the NOT group and 10 in the control group, p=0.98) required LTOT during the whole follow-up (35+/-14 months). Sixteen patients died, nine in the NOT group and seven in the control group (p=0.84). Forty-six patients were able to undergo pulmonary haemodynamic re-evaluation after 2 yrs, 24 in the NOT and 22 in the control group. In the control group, mean resting pulmonary artery pressure increased from 19.8+/-5.6 to 20.5+6.5 mmHg, which was not different from the change in mean pulmonary artery pressure in the NOT group, from 18.3+/-4.7 to 19.5+/-5.3 mmHg (p= 0.79). Nocturnal oxygen therapy did not modify the evolution of pulmonary haemodynamics and did not allow delay in the prescription of long-term oxygen therapy. No effect of NOT on survival was observed, but the small number of deaths precluded any firm conclusion. These results suggest that the prescription of nocturnal oxygen therapy in isolation is probably not justified in chronic obstructive pulmonary disease patients.
Collapse
|
96
|
Schott R, Chaouat A, Tavernier M, Kessler R, Weitzenblum E. [Paraneoplastic hypercorticism associated with a bronchial adenocarcinoma]. Rev Mal Respir 1999; 16:395-7. [PMID: 10472651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Cushing's syndrome is infrequently associated with adenocarcinomas of the lung. We present the clinical features of this syndrome in one case report. The pathogenesis of the syndrome explains the clinical signs, rather different from classical Cushing's disease and also the highly suggestive biological features. Ketoconazole improves clinical signs and biological abnormalities when etiological treatment is not effective.
Collapse
|
97
|
Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115:1748-9. [PMID: 10378581 DOI: 10.1378/chest.115.6.1748] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Pulmonary hypertension at the end stage of chronic liver disease is not an uncommon situation. This association termed portopulmonary hypertension raises the question of the feasibility of performing orthotopic liver transplantation (OLT). In the case reported herein, there was a favorable outcome after OLT, even though the mean pulmonary artery pressure (MPAP) before transplantation was increased to 45 mm Hg. Before OLT, the cardiac index (CI) was considerably elevated (7.69 L/min/m2), giving evidence of a marked hyperdynamic circulatory state. The CI decreased significantly after OLT (3.38 L/min/m2), and this produced a significant decrease in the MPAP. Our observation suggests that portopulmonary hypertension due to a marked increase in the CI can be managed successfully by OLT.
Collapse
|
98
|
Chaouat A, Faller M, Kessler R, Petit H, Schlossmacher P, Schott R, Bugnet AS, Djellid D, Weitzenblum E. [Right-left intra-atrial shunt in the absence of elevated pressures in the right cardiac cavities]. Rev Mal Respir 1999; 16 Suppl 3:S205. [PMID: 10357656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
99
|
|
100
|
Weitzenblum E, Chaouat A, Kessler R, Schott R, Oswald M, Apprill M, Krieger J. [Short-duration nocturnal hypoxemia and persistent pulmonary hypertension]. Rev Mal Respir 1998; 15:743-51. [PMID: 9923028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Can daily short-duration hypoxemia (4-8 hours) induce pulmonary hypertension and right ventricular hypertrophy? A clinical model of this type of hypoxemia does exist: isolated nocturnal hypoxemia in patients with obstructive sleep apnea syndrome (OSAS) or chronic obstructive pulmonary disease (COPD). By investigating the pulmonary hemodynamics of these patients, it should be possible to determine whether nocturnal hypoxemia alone can induce pulmonary hypertension. Although nocturnal hypoxemia (in OSAS as well as in COPD) can induce acute episodes of pulmonary hypertension, it would not appear that nocturnal hypoxemia alone would be sufficient to provoke permanent diurnal pulmonary hypertension. This is the conclusion of recent studies concerning diurnal pulmonary hemodynamics in OSAS and COPD patients exhibiting minimal hypoxemia during the day but significant nocturnal desaturation. The therapeutic consequences of these data, particularly in COPD are important: current evidence is insufficient to treat with nocturnal oxygen therapy COPD patients who have minimal diurnal hypoxemia but significant nocturnal desaturation.
Collapse
|